MDxヘルス
MDxHealth S.A.
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.22 | $27M | -$6M |
| 2025 Q4 | -0.37 | $55M | $324,000 |
| 2025 Q2 | -0.30 | $27M | -$2M |
| 2024 Q4 | -0.54 | $48M | -$9M |
| 2024 Q2 | -0.73 | $42M | -$12M |
| 2023 Q4 | -0.76 | $39M | -$14M |
| 2023 Q2 |
| -1.02 |
| $31M |
| -$13M |
| 2022 Q4 | -2.13 | $24M | -$22M |